Compare AVNT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | VKTX |
|---|---|---|
| Founded | 1927 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2000 | 2014 |
| Metric | AVNT | VKTX |
|---|---|---|
| Price | $43.59 | $33.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $41.50 | ★ $95.86 |
| AVG Volume (30 Days) | 883.1K | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $3,835,500,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | $32.53 | ★ N/A |
| Revenue Growth | ★ 1.71 | N/A |
| 52 Week Low | $27.48 | $22.96 |
| 52 Week High | $46.64 | $43.15 |
| Indicator | AVNT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 47.67 |
| Support Level | $43.12 | $32.24 |
| Resistance Level | $45.21 | $33.77 |
| Average True Range (ATR) | 1.15 | 1.44 |
| MACD | -0.41 | -0.00 |
| Stochastic Oscillator | 37.06 | 38.49 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.